Get Quote

Ningbo JustLive Electrical Appliance Co., Ltd

News

  • LeBron James on passing Kareem Abdul-Jabbar for most postseason field goals: I'm not a scorer
    CLEVELAND – LeBron James said it again. He told reporters how he`s not a scorer. Funny, from the man who is the NBA`s all-time leading playoff scorer and who on Monday passed Kareem Abdul-Jabbar as the league`s all-time playoff leader in made field goals. James scored 44 points on 17-for-28 shooting as the Cavaliers defeated Boston 111-102 in Game 4 on Monday, tying the best-of-7 Eastern Conference finals at 2-all. He now has 2,368 made baskets in the playoffs, 12 more than Abdul-Jabbar and nearly 200 more than Michael Jordan. (We all know James has played more playoff games than Jordan – but not more than Abdul-Jabbar). [Listen, any time I'm in the same breath with the greats, I know you guys hear me say it over and over, it's just humbling," James said. He likes to say that, too, how much it`s an honor just to hear his name mentioned with Hall of Famers. [I was a kid and I watched the playoffs so much and I was like, I would love to be a part of that, that moment, that atmosphere," James said. [I think it's pretty cool. You hear the scoring, the field goals made – and for a kid who really doesn't care much about scoring." More NBA LeBron James scores 44 as Cavs hold off feisty Celtics to even series 2-2 Cleveland Cavaliers coach Ty Lue couldn't believe how old Kyle Korver is No one knows who`s going to win this series. [Only the game gods know that," James said. But this chorus is on repeat: Beating James four times in an East playoff series is the hardest task in the NBA. Yes, the Celtics took a 2-0 lead, and yes, teams with a 2-0 lead have won the series 94% of the time. But of the 19 teams to come back from a 2-0 deficit and win the series, James was on two of those teams. If you`re putting your chips on one player in today`s game to do it, it`s James. At 33, James has put together one of his finest postseason efforts, averaging a playoff career-high 33.7 points, nine assists and 8.7 rebounds and shooting 55% from the field. [It's something that people shouldn't take for granted," Celtics center Al Horford said. [He's doing great things." In Game 4, James found mismatches, taking advantage of Terry Rozier and Jaylen Brown. It didn`t help that Marcus Morris was in foul trouble, picking up three in the first quarter. Boston has made it tough on James, especially in Game 1. He had a 40-point triple-double in the Celtics' Game 2 victory, but he found easier offense in the two games in Cleveland. [He's the best in the game at evaluating the court and figuring out what he wants and where he wants it," Celtics coach Brad Stevens said. [The thing about it is that you just have to battle. You just have to make it as hard as possible, because he's going to find a matchup that he ultimately wants. - He's going to go after whoever he wants to go after." James went to work early, scoring 11 points in the first quarter and 11 in the second. He had 13 in the third and nine in the fourth. (An aside: James has never scored 50 or more points in a playoff game). [I'm just watching them, breaking down film and seeing what's the best possible chance for us to be successful versus their defense," James said. [This league is all predicated on trying to find mismatches. That's every team. [If you look at the four teams in the postseason now, Houston is trying to find mismatches, Golden State is trying to find mismatches, Boston, and us as well. We're all trying to find mismatches for us to try to be successful offensively. It's not much of a secret." James joined Jerry West, Bernard King, Michael Jordan and Allen Iverson as the only players to score at 40 points six times in a one postseason. He worked over Boston with his low-post, mid-range and dribble-and-attack game. But nope, he`s not a scorer. Not LeBron James. Not the guy who might finish his career in the top three in points, if not pass Abdul-Jabbar for the top spot. Follow USA TODAY Sports' Jeff Zillgitt on Twitter. If you are looking for a trustable supplier for Heating Pads, try to find us at www.makeheat.net. We are always better than you expect!

    2018 05/24

  • FDA renew 2017
    CONGRATULATIONS !!! Our FDA registration has been renewed to 2017 for Heating Pads.

    2016 12/27

  • Top 3 Motorcycle Tyre Warmers
    As you get more into track days and your pace starts to increase you will no doubt think about investing in various items to make your experiences on track easier and/or more enjoyable. One of the most popular first investments for track riders is motorcycle tyre warmers. Tyre warmers do exactly what they say on the tin – they warm tyres. They`re used to get some initial heat in both the tyre and the rim before heading out on track. This is beneficial for a number of reasons. The Benefits of Tyre Warmers While they won`t bring the tyres up to full operating temperature, having some heat built up deep in the carcass of the tyre will save time early on in a session because you won`t have to take as long building up your speed. This initial heat will also give you a sort of safety net and reduce the risk of having a cold tyre crash. Another benefit is the extra life they give your tyres. They do this by both reducing the extent and amount of heat cycles the tyres go through (assuming you put them on as soon as you come back in from a session), and by reducing the chance of unsavoury wear due to the surface of the tyre heating up quicker than the carcass of the tyre (cold tearing). This ultimately means your tyres will perform that much better, for longer. Lastly, they can give you comfort mentally because you know you`ve got a good deal of heat built up in the tyres before you head out. This is the main reason why I personally invested in them, and in my early track life it did wonders for my confidence early on in a session and saved me tip toeing around for too long wondering if I was building up enough heat. It is worth mentioning however that you should still take it easy early on in a session and build up your speed. As said, tyre warmers won`t bring your tyres up to the sort of temperatures they`ll reach on the track, so you still need to build up that bit of extra heat, and in turn performance potential during the start of a session. Do you need them? If the question is do you need them to enjoy track days? No, of course not. But for the benefits they`ll give you in terms of personal confidence, saved time and tyre life, then I personally would say they are a worthwhile investment for anyone who is getting more into their track days. Holroyd Race-Tech The Race-Tech tyre warmers are by far the cheapest option here, but you`d be wrong to think that as a result they are an inferior option. Holroyd are specialists in manufacturing heating elements for various applications, and with over 40 years in the business you`d like to think they know a thing or two about producing good quality, reliable heating elements. I actually own a set of Holroyd`s Race-Tech warmers. I have been using them for two seasons now and in that time they have served their purpose flawlessly and aren`t showing any signs of wear from use, which shows they are in fact well made. They don`t get as hot as some of the other options here and there is no variable temperature feature, but tyres come out of the warmers hot to the touch which will be sufficient for riders at track day level. It`s also worth mentioning that they are British made and the customer service is second to none. Click to see prices for Holroyd Race-Tech tyre warmers CAP-IT Warmers Coming out of Italy we have CAP-IT tyre warmers. They are considered as being one of the best set of warmers on the market in terms of quality and performance, and given the fact they are used by teams in MotoGP would more than likely justify that statement. This top level use though comes at a cost to the consumer, and the high quality of the product coupled with them being used at the highest level means there is a premium to pay, coming in at nearly three times the price of the Race-Techs. However, I`ve heard quite a few people comment that they`re happy they paid the extra and are easily the best warmers they`ve ever used. Click to see prices for CAP-IT tyre warmers Diamond Warmers Another pair coming out of Britain, made by Diamond Race Products. The company produce a whole manner of different motorcycle race products, one of which is tyre heaters. Diamond`s warmers are used by top teams in both the British and World Superbike Championships, which again demonstrates that they perform to the highest standard. As with the CAP-IT warmers though, this high performance standard and the high status use means they too are a great deal more expensive. I have used a set of Diamond tyre heaters on a number of occasions (usually when I`ve forgot my own) and they are in fact very good quality and they do feel like they get the tyres a little hotter. Click to see prices for Diamond tyre warmers What I`d buy As I commented above, I currently own a set of Holroyd Race-Tech tyre warmers, but if I had to buy another set, I could honestly see myself opting for the same pair again. At no point in the two seasons I have used them have I ever felt they weren`t doing the job as well as they could. They heat up the tyre sufficiently (as I said the tyres come out hot to the touch, not warm), they haven`t gone wrong, and they don`t look like there`s any wear through use. If I was being picky I would argue that the drawstring system that`s used to close the tyre up around the tyre can be a little finicky at times and get caught in the wheel, but it`s not really something that concerns me too much. I`ve no doubt that the extra dosh paid on the Diamond or CAP-IT warmers will mean you see some extra quality and better performance, but I don`t think I could warrant spending double (if not triple) the price of the Holroyds, which currently provide a perfectly adequate means of heating tyres for track days. So if it was my money, I`d buy the Race-Techs--.again.

    2016 12/27

  • Best Heating Pads for Pain Relief
    Heating pads are very useful to put on all of your sore muscles-back of the neck, on your lower lumbar and all back areas, shoulders, hips, knees, legs, and feet. The best heating pads are very helpful for menstrual cramps and great for cold feet in the winter when socks don`t get you warm enough when you sit in your recliner watching a movie. A heating pad is simply becoming familiar with the different types in the marketplace and choosing the one that best suits you and your family`s needs. Most of the time they sit in the linen closet, but oh how wonderful it is to have it nearby when feeling achy and sore. They are better to use than painkillers with no side effects. Heating pads are a staple, just like having bath towels and peanut butter. How Heating Pads Work to Relieve Pain Warmth, heat, and a history for being related to relaxation and comfort is the heating pad. Heat remedies offer equally great pain relief and therapeutic advantages for many types of lower back pain and all body aches and muscle soreness. This is an inexpensive way to achieve results for strains and sprains. It also will help when you over extend your muscles anywhere that feel tense and sore. Heat does ease tightness in the lower back. Heat dilates the blood vessels increasing blood flow carrying nutrients and oxygen to the muscle tissue to help heal. Heat encourages the pain receptors in the skin to reduce the pain signals sent to the brain that will help relieve pain. Heat makes it easy to stretch the soft tissue around the spine, bones, muscle tissue, scar tissue, and supportive and connecting tissues and organs of the body. With heat on your body, stiffness and improved flexibility will happen. Taking a hot bath or shower is recommended before getting under the heating pad. Heating pads are an easy solution that can be done at home while relaxing. You can take small ones to the office to use on your lower back. Portable heat wraps are another option for taking with you to work or use in the car or truck. Heating pads are not invasive, require no doctor prescriptions, and provide relief. How to Use Heat Therapy First, read the instructions that come with your heating pad including the warnings and cautions. Generally, a pulled muscle or sprain is the most frequent beginning of back pain-upper, lumbar, and lower. The pain usually lasts from a couple of days to a few weeks. A lumbar cushion might be beneficial in conjunction with a heating pad. Alternatively, have someone give you a great relaxing massage with a hand-held massager. You will want a heating pad that maintains its heat at the appropriate temperature. Warm is the ideal and suitable temperature for muscle pain. The heat needs to pass through the skin without burning the skin to get into the muscles. Making the skin hot does nothing for the muscles-in fact, it will distract you giving you more pain from heat! Sustained heat is best. Slight pain or injuries can be done in shorter times of 15 to 20 minutes while more extreme pain might take longer times of heat up to 3 hours and more. Plug the heating pad into the wall outlet, set the dials or control, kick back with a good book or movie, and relax. When Not to Use Heat Therapy To be on the safe side, always discuss heat therapy using heating pads with your doctor. Please talk with your healthcare provider if you have high blood pressure (hypertension), or heart disease. You should not use heat if you have: Diabetes Peripheral artery disease (PAD) or sometimes called peripheral vascular disease Dermatitis Lower back bruising or swelling Open sores or wounds Deep vein thrombosis (DVT), a blood-clotting disorder Mental challenges If you are bruised or have swelling, an ice or cold pack would be the best thing to reduce swelling, not heat.

    2016 11/29

  • ISO9001:2008
    We now have obtained ISO9001:2008 certificate. 2016.10.13

    2016 10/14

  • Heating Pad Business Expands To South America
    Good news. Our former businesses mainly covered North America (especially United States, taking up almost 70%), Europe (The Netherlands, Greece, France, Russia, Spain etc.) and Middle East (Iran), but now we also expand to South America (Ecuador). We sincerely welcome customers from anywhere of the world come to do businesses with us. Our particular products are Heating Pad, electric underblanket, overblanket, electric cape, plate warmer etc.. Best Regards Ningbo MakeHeat Electrical Appliance Co., Ltd 2016.04.25

    2016 04/25

  • Office Opened 2016
    Dear Customers, We have reverted back to normal work already on Feb. 15. The factory headquarter will be opened on Feb. 18. Looking forward to do continuous businesses together with you in 2016. Ningbo Makeheat Electrical Appliance Co., Ltd 2016.02.15

    2016 02/15

  • CNY 2016
    Our factory will be closed for CNY 2016 holiday since Feb. 4th and come back on Feb. 15th. As a professional manufacturer of heating pads and electric blankets, we will still have email access during the holiday. So, if you have any inquiries, pls feel free to find us. Ningbo Makeheat Electrical Appliance Co., Ltd 2016-01-29

    2016 01/29

  • ALDI Receives the Heating Pads
    Good news!!! ALDI USA has successfully received our heating pads, and according to our customer, the selling is quite good till now. 2016-01-29

    2016 01/29

  • Walgreens Boots Alliance Reports Fiscal 2016 First Quarter Results
    07 January 2016 Adjusted first quarter net earnings attributable to Walgreens Boots Alliance per diluted share increase 32.1 percent to $1.03 compared with the year-ago period; GAAP net earnings attributable to Walgreens Boots Alliance per diluted share increase 13.5 percent to $1.01 Adjusted first quarter net earnings attributable to Walgreens Boots Alliance increase 51.1 percent to $1.1 billion compared with the year-ago period; GAAP net earnings attributable to Walgreens Boots Alliance increase 30.6 percent to $1.1 billion GAAP operating cash flow totals $732 million in the quarter, while free cash flow totals $392 million Company raises by 5 cents per share its low end of guidance for fiscal year 2016 anticipated adjusted net earnings per diluted share attributable to Walgreens Boots Alliance to $4.30 to $4.55 DEERFIELD, Ill. (BUSINESS WIRE), 07 January 2016 - Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the first quarter 2016 that ended 30 November 2015. Executive Vice Chairman and CEO Stefano Pessina said, [The year has started with a comparatively strong first quarter, as we expected. Our ongoing work to control costs across Walgreens Boots Alliance and improve adjusted operating income margins is growing earnings overall. Although it is early in the year, we are on track to deliver against our expectations. [The work to renew and update our businesses, in order to meet the opportunities and challenges of our ever-changing markets, is a core strength that we must embrace as routine across our enterprise. Our ability to deploy tools and strategies that address these dynamics, generating continued growth across Walgreens Boots Alliance, and the commitment I see from our team give me confidence that we will deliver what we have signaled for 2016 and beyond." Overview of First Quarter Results Fiscal 2016 first quarter net earnings attributable to Walgreens Boots Alliance determined in accordance with GAAP increased 30.6 percent to $1.1 billion compared with the same quarter a year ago, while GAAP net earnings attributable to Walgreens Boots Alliance per diluted share increased 13.5 percent to $1.01 compared with the same quarter a year ago. Adjusted fiscal 2016 first quarter net earnings attributable to Walgreens Boots Alliance1 increased 51.1 percent to $1.1 billion compared with the same quarter a year ago. Adjusted net earnings attributable to Walgreens Boots Alliance per diluted share for the quarter increased 32.1 percent to $1.03 compared with the same quarter a year ago. Fiscal 2016 first quarter earnings adjustments were a net increase to GAAP net earnings attributable to Walgreens Boots Alliance of $22 million or 2 cents per diluted share. Net sales in the first quarter increased 48.5 percent to $29.0 billion compared with the same quarter a year ago, largely due to the inclusion of Alliance Boots consolidated results. Combined net synergies in the fiscal 2016 first quarter were $288 million. The company continues to expect to reach at least $1.0 billion in combined net synergies in fiscal 2016 relating to the strategic combination with Alliance Boots. This excludes the synergy benefits related to the company`s strategic, long-term relationship with AmerisourceBergen, the benefits of refinancing the legacy Alliance Boots indebtedness at a lower cost and the proposed Rite Aid acquisition. Walgreens Boots Alliance GAAP operating cash flow totaled $732 million in the first quarter, while the company generated free cash flow of $392 million in the quarter. Rite Aid Acquisition Walgreens Boots Alliance`s proposed acquisition of Rite Aid Corporation is progressing as planned. The transaction, which was announced 27 October 2015, is subject to the approval of Rite Aid`s stockholders, the expiration or termination of applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and other customary closing conditions. Rite Aid has scheduled a special meeting of its stockholders for 4 February 2016 to, among other things, consider and vote on a proposal to approve the Agreement and Plan of Merger related to the proposed acquisition. As a standard part of the regulatory process in connection with the Federal Trade Commission`s (FTC) review, Walgreens Boots Alliance and Rite Aid last month each received, as expected, a request for additional information from the FTC in connection with the proposed acquisition. Walgreens Boots Alliance continues to expect the transaction to close in the second half of calendar 2016. The company`s integration planning continues. In addition, in connection with the acquisition, the company last month completed the placement of $5 billion term loan facilities and the syndication of a new $7.8 billion bridge facility. These new facilities replaced the company`s previously reported $12.8 billion bridge facility commitment. Drawing under the facilities is subject to the closing of the acquisition. Company Outlook The company is raising by 5 cents per share its low end of guidance for fiscal year 2016 anticipated adjusted net earnings per diluted share attributable to Walgreens Boots Alliance to $4.30 to $4.55. This guidance continues to assume no material accretion from the proposed acquisition of Rite Aid. Business Segment Highlights Retail Pharmacy USA: The Retail Pharmacy USA division, whose principal retail pharmacy brands are Walgreens and Duane Reade, had first quarter total sales of $20.4 billion, an increase of 4.2 percent over the year-ago quarter. Sales in comparable stores increased 5.8 percent compared with the same quarter a year ago. Pharmacy sales, which accounted for 68.4 percent of division total sales in the quarter, increased 6.7 percent compared with the year-ago quarter, while comparable pharmacy sales increased 9.3 percent. The company attributed the increase in pharmacy sales in part to growth in Medicare Part D and an increase in focus on pharmacy customer care. The division filled 231 million prescriptions (including immunizations) adjusted to 30-day equivalents in the quarter, an increase of 4.1 percent over last year`s first quarter, while the reported incidence of flu across the USA declined 10.7 percent compared with the year-ago quarter, according to IMS Health. Prescriptions filled in comparable stores increased 4.7 percent compared with the same quarter last year. The division`s retail prescription market share on a 30-day adjusted basis in the first quarter increased approximately 20 basis points over the year-ago quarter to 19.2 percent, as reported by IMS Health. Walgreens new U.S. fulfillment agreements with Valeant Pharmaceuticals International Inc., announced on 15 December 2015, are expected to enhance the division`s pharmacy market share growth as the agreements are rolled out in calendar 2016. Comparable retail sales decreased 0.6 percent in the first quarter primarily due to a reduction in unprofitable promotions and the transitioning of seasonal items away from holiday decorations and toward higher quality, giftable items. Adjusted gross profit dollars for the division grew $143 million to $5.5 billion compared with the same quarter a year ago. At the same time, gross profit margins were negatively impacted, as expected, by lower pharmacy reimbursement rates, an increase in Medicare Part D prescriptions and the mix of specialty medications. Adjusted first quarter selling, general and administrative expenses in the division decreased by $89 million, or 2.1 percent, compared with the year-ago quarter. The strong cost control resulted from good progress within the division as part of Walgreens Boots Alliance`s previously announced $1.5 billion cost transformation program, designed to restructure and invest in the company`s future in a way that is better for customers and simpler for employees, resulting in a faster and more agile company. The division`s GAAP operating income in the fiscal 2016 first quarter decreased 2.5 percent over the year-ago quarter to $1.0 billion. Adjusted operating income in the first quarter increased 11.2 percent over the year-ago quarter to $1.2 billion. The fiscal 2016 first quarter for the Retail Pharmacy USA division includes results of operations, the allocation of synergy benefits including Walgreens Boots Alliance Development GmbH (WBAD) and an allocation of combined corporate costs. The fiscal 2015 first quarter included all corporate costs of Walgreen Co., the full consolidated results of WBAD and equity income from Walgreen Co.`s pre-closing 45 percent interest in Alliance Boots. Excluding the impact from Alliance Boots equity income, the division`s adjusted operating income in the first quarter increased 22.9 percent over the year-ago quarter. Retail Pharmacy International: The Retail Pharmacy International division, whose principal retail brands are Boots in the UK, Thailand, Norway, the Republic of Ireland and The Netherlands, Benavides in Mexico and Ahumada in Chile, had first quarter total sales of $3.5 billion. On a pro forma constant currency basis, comparable store sales in the first quarter increased 2.2 percent compared with the same period a year ago, with particularly strong growth in Mexico and the Republic of Ireland. Comparable pharmacy sales increased 3.8 percent in the first quarter compared with last year`s first quarter, driven by good growth in dispensing and pharmacy services in the UK and Mexico. Comparable retail sales increased 1.3 percent in the quarter compared with the same period a year ago, with strong growth in Ireland. Boots UK also grew due to good performances in retail healthcare and beauty, supported by continued growth in boots.com. GAAP operating income was $302 million, while adjusted operating income was $315 million. Pharmaceutical Wholesale: The Pharmaceutical Wholesale division, which mainly operates under the Alliance Healthcare brand, had first quarter total sales of $5.8 billion. On a pro forma constant currency basis and excluding acquisitions and dispositions, comparable sales increased 3.1 percent compared with the same period a year ago. Sales growth in the quarter was particularly strong in Norway, while solid growth continued in Germany and Turkey, two of the division`s largest markets. GAAP operating income was $143 million, while adjusted operating income was $166 million. Comparability of Results Walgreens Boots Alliance has organized its operations and reports results in three segments: Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. Segmental reporting includes the allocation of synergy benefits, including WBAD`s results, and the combined corporate costs for periods subsequent to 31 December 2014. The company has determined that it is impracticable to allocate historical results to the current segmental presentation. Following the combination, the company eliminated the three-month reporting lag and recast prior period results with no lag. The combination on 31 December 2014 also means fiscal year 2015 reporting includes the results of Alliance Boots for eight months (January through August 2015) on a fully consolidated basis and four months (September through December 2014) as equity income from Walgreen Co.`s pre-closing 45 percent interest. The company's balance sheet reflects the full consolidation of Alliance Boots assets and liabilities as a result of the close of the combination on 31 December 2014. The company's purchase accounting remains preliminary as contemplated by U.S. generally accepted accounting principles (GAAP) and, as a result, there may be upon further review future changes to the value, as well as allocation, of the acquired assets and liabilities, associated amortization expense, goodwill and the gain on the previously held equity interest. Year-over-year comparisons of results require consideration of the foregoing factors and are not directly comparable. Conference Call Walgreens Boots Alliance will hold a one-hour conference call to discuss the first quarter results beginning at 8:30 a.m. Eastern time today, 7 January 2016. The conference call will be simulcast through the Walgreens Boots Alliance investor relations website at: http://investor.walgreensbootsalliance.com. A replay of the conference call will be archived on the website for 12 months after the call. The replay also will be available from 11:30 a.m. Eastern time, 7 January 2016 through 14 January 2016, by calling 855-859-2056 within the USA and Canada, or 404-537-3406 outside the USA and Canada, using replay code 93731993. 1 Please see the [Reconciliation of Non-GAAP Financial Measures" table and accompanying disclosures at the end of this press release for more detailed information regarding non-GAAP financial measures herein, including the items reflected in adjusted net earnings calculations. Cautionary Note Regarding Forward-Looking Statements: All statements in this release that are not historical including, without limitation, estimates of and goals for future financial and operating performance (including those under [Company Outlook" above), the expected execution and effect of our business strategies, our cost-savings and growth initiatives and restructuring activities and the amounts and timing of their expected impact, and our pending agreement with Rite Aid and the transactions contemplated thereby and their possible effects, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "likely," "outlook," "forecast," [preliminary," "would," "could," "should," "can," "will," "project," "intend," "plan," "goal," [guidance," "target," "continue," "sustain," "synergy," "on track," "believe," "seek," "estimate," "anticipate," "may," "possible," "assume," and variations of such words and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that could cause actual results to vary materially from those indicated, including, but not limited to, those relating to the impact of private and public third-party payers` efforts to reduce prescription drug reimbursements, the impact of generic prescription drug inflation, the timing and magnitude of the impact of branded to generic drug conversions, our ability to realize anticipated synergies and achieve anticipated financial, tax and operating results in the amounts and at the times anticipated, supply arrangements including our commercial agreement with AmerisourceBergen Corporation, the arrangements and transactions contemplated by our framework agreement with AmerisourceBergen and their possible effects, the risks associated with equity investments in AmerisourceBergen including whether the warrants to invest in AmerisourceBergen will be exercised and the ramifications thereof, the occurrence of any event, change or other circumstance that could give rise to the termination, cross-termination or modification of any of our contractual obligations, the amount of costs, fees, expenses and charges incurred in connection with strategic transactions, whether the actual costs associated with restructuring activities will exceed estimates, our ability to realize expected savings and benefits from cost-savings initiatives, restructuring activities and acquisitions in the amounts and at the times anticipated, the timing and amount of any impairment or other charges, changes in management`s assumptions, the risks associated with governance and control matters, the ability to retain key personnel, changes in economic and business conditions generally or in the markets in which we participate, changes in financial markets, interest rates and foreign currency exchange rates, the risks associated with international business operations, the risk of unexpected costs, liabilities or delays, changes in vendor, customer and payer relationships and terms, including changes in network participation and reimbursement terms, risks of inflation in the cost of goods, risks associated with the operation and growth of our customer loyalty programs, risks associated with acquisitions, divestitures, joint ventures and strategic investments, including our ability to satisfy the closing conditions and consummate the pending acquisition of Rite Aid and related financing matters on a timely basis or at all, the risks associated with the integration of complex businesses, subsequent adjustments to preliminary purchase accounting determinations, outcomes of legal and regulatory matters, including with respect to regulatory review and actions in connection with the pending acquisition of Rite Aid, and changes in legislation, regulations or interpretations thereof. These and other risks, assumptions and uncertainties are described in Item 1A (Risk Factors) of our Annual Report on Form 10-K for the fiscal year ended 31 August 2015, which is incorporated herein by reference, and in other documents that we file or furnish with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Except to the extent required by law, we do not undertake, and expressly disclaim, any duty or obligation to update publicly any forward-looking statement after the date of this release, whether as a result of new information, future events, changes in assumptions or otherwise. Please refer to the supplemental information presented below for reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP financial measure and related disclosures. Notes to Editors: About Walgreens Boots Alliance Walgreens Boots Alliance (Nasdaq: WBA) is the first global pharmacy-led, health and wellbeing enterprise. The company was created through the combination of Walgreens and Alliance Boots in December 2014, bringing together two leading companies with iconic brands, complementary geographic footprints, shared values and a heritage of trusted health care services through pharmaceutical wholesaling and community pharmacy care, dating back more than 100 years. The company employs more than 370,000* people and has a presence in more than 25* countries; it is the largest retail pharmacy, health and daily living destination in the USA and Europe. Including its equity method investments, Walgreens Boots Alliance is a global leader in pharmacy-led, health and wellbeing retail with over 13,100* stores in 11* countries. The company includes one of the largest global pharmaceutical wholesale and distribution networks with over 350* distribution centers delivering to more than 200,000** pharmacies, doctors, health centers and hospitals each year in 19* countries. In addition, Walgreens Boots Alliance is one of the world`s largest purchasers of prescription drugs and many other health and wellbeing products. Its portfolio of retail and business brands includes Walgreens, Duane Reade, Boots and Alliance Healthcare, as well as increasingly global health and beauty product brands, such as No7, Botanics, Liz Earle and Soap & Glory. More company information is available at www.walgreensbootsalliance.com. * As at 31 August 2015 including equity method investments ** For 12 months ended 31 August 2015 including equity method investments (WBA-ER)

    2016 01/12

  • FDA 2016 Registration
    Good news. Our FDA registration has been updated to the year 2016. It will be valid till Dec. 31, 2016. Ningbo Makeheat Electrical Appliance Co., Ltd 2015-12-23

    2015 12/23

  • MedTrade 2016
    One of the world's leading healthcare exhibitions "MedTrade" will be held from Oct 31 - Nov 3, 2016. We look forward to meeting you then in Atlanta.

    2015 11/17

  • Medica 2015
    The world`s leading medical trade fair, MEDICA, is going to start with a significant change. From this year on, the event will cover the four days from Monday to Thursday. We look in advance at exciting research topics, major health policy and economic questions for you at MEDICA-tradefair.com. Feel free to check out those and more for yourself from 16th to 19th November in Düsseldorf. Read more about surgical robots from space, future hybrid ORs and the responsibility of health industry towards the patients.

    2015 11/17

  • FDA Releases Final Guidance on Reprocessing of Reusable Medical Devices
    The U.S. Food and Drug Administration today announced new actions to enhance the safety of reusable medical devices and address the possible spread of infectious agents between uses. The new recommendations are outlined in a final industry guidance aimed at helping device manufacturers develop safer reusable devices, especially those devices that pose a greater risk of infection. Medical devices intended for repeated use are commonplace in health care settings. They are typically made of durable substances that can withstand reprocessing, a multi-step process designed to remove soil and contaminants by cleaning and to inactivate microorganisms by disinfection or sterilization. While the majority of reusable devices are successfully reprocessed in health care settings, the complex design of some devices makes it harder to remove contaminants. FDA`s guidance document, titled [Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling" includes recommendations medical device manufacturers should follow pre-market and post-market for the safe and effective use of reprocessed devices. A device manufacturer`s reprocessing instructions are critical to protect patients against the spread of infections. As part of its regulatory review for reusable medical devices, the FDA reviews the manufacturer`s reprocessing instructions to determine whether they are appropriate and able to be understood and followed by end users. The guidance lists six criteria that should be addressed in the instructions for use with every reusable device to ensure users understand and correctly follow the reprocessing instructions. The guidance also recommends that manufacturers consider reprocessing challenges early in device design. Manufacturers will be expected to conduct validation testing to show with a high degree of assurance that their cleaning and disinfection or sterilization instructions will consistently reduce microbial contamination. [Despite the recent concerns about multi-drug resistant bacteria infections associated with duodenoscopes, patients and health care providers should know that the risk of acquiring an infection from a reprocessed medical device is low" said William Maisel, M.D., M.P.H., deputy director for science and chief scientist at the FDA`s Center for Devices and Radiological Health. [This guidance is an important step toward further enhancing the safety margin by outlining for manufacturers the steps they should undertake to make their reprocessing instructions effective and clear to the healthcare community that uses them. Doing so should provide greater assurance to patients that the devices used on them are safe and effective." The FDA issued a draft guidance discussing the reprocessing of reusable medical devices in 2011, and considered almost 500 comments before issuing the final guidance. The final guidance provides more clarity about testing protocols and what data should be submitted to the agency for a premarket submission, such as the data FDA needs to evaluate substantial equivalence for a 510(k) premarket submission. Manufacturers seeking to bring to market certain reusable devices, such as duodenoscopes, bronchoscopes and endoscopes, should submit to the FDA for review their data validating the effectiveness of their reprocessing methods and instructions. Separately, the FDA also announced in the Federal Register that the agency`s Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee will hold a public meeting on May 14 and 15, 2015 to discuss recent reports and epidemiologic investigations of transmission of infections associated with the use of duodenoscopes in endoscopic retrograde cholangiopancreatography (ERCP) procedures in hospitals in the United States. The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation`s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

    2015 10/22

  • Electric Blanket
    Blanket, also known as electric mattress, is a contact with a heater, it special, insulating properties up to standard soft rope heating elements were woven into a serpentine shape or sewn into blankets that emit heat when energized. Working principle and structure as well as a similar blanket warm dressing blanket, electric mattress and the heating pad. Blanket Advantage 1. It has a rheumatic pain, people have a good protective effect, can reduce the chance of their attack. 2. In addition to the constitution particularly the elderly or people with weakened, electric blankets can also provide better care. Who should not use electric blankets: 1, suffering from tracheitis, bronchitis, emphysema and asthma and other respiratory diseases, long-term use of electric blankets easily exacerbate the condition; 2, inflammation and allergies should not be used; 3, patients with bleeding disorders, such as: bleeding, tuberculosis hemoptysis, bleeding ulcer or stroke, etc., because the blanket will accelerate blood circulation, dilation of blood vessels, thus exacerbating the bleeding; 4, cardiovascular and cerebrovascular disease should not be used; 5, infants, pregnant women, etc. unfit men of reproductive age use electric blankets. Despite blanket has become a good helper to resist cold, low power consumption, temperature can be adjusted, easy to use, widely, but use the time to pay more attention! To ensure safe and healthy! Blanket Safety Knowledge To ensure the safety of family use electric blankets and electric blankets to extend the service life, prevent and avoid the use of unsafe factors blanket process, please note the following: 1. Before using the blanket, you should read the manual, in strict accordance with the instructions. 2. Use a power supply voltage and frequency to be consistent with the blanket calibration rated voltage and frequency. 3. folded blanket should be strictly prohibited to use. The process of using electric blankets, electric blanket should always check whether there set the heap, pleated phenomenon, and if so, should be used after smoothing wrinkles. 4. Do not blanket together with other heat sources. 5. The use of preheat electric blanket should be absolutely prohibited the use of electricity overnight, when the user bed, turn off the power. 6. Baby and life can not take care of themselves do not use electric blankets alone should have someone before use. 7. Do not place sharp hard object on the blanket, not the blanket on the protruding metal or other sharp or hard objects to use.

    2015 10/22

  • Stimulating Investor Interest: Setpoint adds $15M to Series C for bioelectronic anti-inflammatory tech
    A private company taking a unique approach to treating inflammatory diseases like rheumatoid arthritis (RA) andCrohn's disease has attracted new financial support in the form of a $15 million extension to its Series C financing, bringing the total of the round to $43 million. Setpoint (Valencia, Calif.) said it will use the proceeds for clinical trials of itsbioelectronic therapy in RA and Crohn's, and to help advance the therapy toward commercialization. Setpoint's therapy uses an implanted device to stimulate the vagus nerve, activating the body's inflammatory reflex to provide an anti-inflammatory effect. The Series C1 round includes a new strategic investor, but the name of that company was not disclosed. Setpoint CEO Anthony Arnold told Medical Device Daily the company already had three major companies heavily invested in Setpoint, making the anonymous new investor the fourth company to show an interest in the therapy, a rare occurrence in the device industry. Setpoint's current investors include Morgenthaler Ventures, Foundation Medical Partners, Topspin Partners, Covidien Ventures, Action Potential Venture Capital Limited and Boston Scientific. "The investors really see a tremendous potential," Arnold said, noting that the market for inflammatory drugs is estimated at $30 billion to $40 billion. "[Investors] see a really unique therapy that might offer patients a relatively simple set-it-and-forget-it type treatment for their disease with few side effects. While those claims remain to be proven in the clinic, he said the therapy is differentiated enough to stimulate investor interest. While Setpoint's technology has been lumped together with neuromodulation, Arnold said the company prefers the term bioelectronic medicine because the device is used much more like a medicine than a neuromodulation system. "The signals our therapy sends are very similar to a neuromodulation therapy," Arnold said. The difference, he said, is that traditional neuromodulation devices are designed to offer immediate therapy once the system is turned on. The Setpoint device, on the other hand, works more like a drug in the sense that the patient does not receive an immediate benefit. Instead, the device is designed to flip a switch in the inflammatory reflex, allowing the body to do the rest of the work. "With other stimulators, they're doing the work. With ours, it's a little more like a drug per say than a traditional neuromodulation therapy," Arnold said. The company launched a small proof-of-study late last year to assess the safety and efficacy of the therapy in up to 15 Crohn's patients at five European centers, after seeing positive results with the technology for RA (Medical Device Daily, Dec. 22, 2014). The trial, which is recruiting patients with moderately-to-severely active Crohn's despite treatment with a tumor necrosis factor antagonist drug, was welcome news in the inflammatory bowel disease community because the disease has traditionally been treated with drugs, dietary changes and surgery and there is currently no standard treatment that works for all patients. But Arnold told MDD the study has been slow to get off the ground because the individual European center approvals took "considerably longer" than Setpoint anticipated. So far only about four patients have been implanted with the device as part of that trial, he said. "This is really an unusual trial, not something they've ever seen, using a medical device for a disease that has always been treated with surgery or drugs," Arnold said. "They had a lot of questions about why we believe the therapy might work and wanting to really understand the mechanism before they approved it." The Series C money will be used to develop Setpoint's first-in-human trials. Arnold said earlier proof-of-concept studies actually evaluated an existing device on the market that the company modified to prove the therapy's potential for RA patients, then the company began to develop its own device. He said the firm's goal is to have the device ready for U.S. human trials in the next 30 months. In other financing activity, Amedica (Salt Lake City), a biomaterial company that makes silicon nitride as a platform for biomedical applications, reported an agreement with institutional investors to raise up to $15 million in a concurrent registered direct offering of common stock and Series B warrants and private placement of Series A warrants and Series C warrants. Amedica entered a settlement agreement with MG Partners II and amended its loan agreements with Hercules Technology Growth Capital. The settlement with Magna provides for the withdrawal of a default notice and permanent waivers of any contractual rights. As part of the Hercules amended loan agreement, Hercules has also withdrawn its default notice and agreed to reduce the company's financial cash covenant as the loan is paid. The transaction is expected to execute in three equal tranches. The first tranche is a registered direct offering of 13,123,360 shares of common stock and Series B warrants to purchase 13,123,360 shares of common stock for a price of $0.381 a share and Series B warrant. The Series B and C warrants have an exercise price of 47 cents and are exercisable up to Dec. 30, 2015. The first tranche also includes a concurrent private placement of Series A warrants and Series C warrants, each to purchase 13,123,360 shares of common stock. The Series A warrants have an exercise price of 47 cents and are exercisable for 5.5 years. The company expects proceeds of about $5 million from this first tranche, which is expected to close on Friday. Ladenburg Thalmann & Co., a subsidiary of Ladenburg Thalmann Financial Services, is acting as exclusive placement agent in connection with the transaction. //

    2015 09/09

  • BSCI Inspection
    GREAT NEWS!!! Ningbo Makeheat Electrical Appliance Co., Ltd has successfully passed BSCI inspection in June 2015, invited by ALDI USA. The inspection was launched by TUV Rheinland. Administrative Department Ningbo Makeheat Electrical Appliance Co., Ltd 2015-07-09

    2015 07/10

  • ETL Certificate Update
    Ningbo Makeheat Electrical Appliance Co., Ltd has developed a new heating pad item named as JY6103, with the size of 7"x19". The ETL tests have been finished, hence the previous certificate is being updated by adding this new item. The certificate has been updated in March, 2015.

    2015 03/10

  • 2015 Spring Holiday
    Ningbo Makeheat Electrical Appliance Co., Ltd will be closed down for Chinese New Year holiday from Feb. 14th to Feb. 25th. Office will be opened on Feb. 26th, 2015. HAPPY NEW YEAR !!!

    2015 02/12

  • FDA Inspection 2014-11
    FDA is an agency within the Department of Health and Human Services. The FDA's organization consists of the Office of the Commissioner and four directorates overseeing the core functions of the agency: Medical Products and Tobacco, Foods, Global Regulatory Operations and Policy, and Operations. FDA carried out a compulsory inspection to Ningbo Makeheat Electrical Appliance Co., Ltd between Nov. 10-13, 2014. The inspection flow was mainly below: Portion of every part is mainly defined as below: We had passed the inspection successfully without any defection. Ningbo Makeheat Electrical Appliance Co., Ltd Youping Chueng President Feb. 05, 2015

    2015 02/05

Email to this supplier

-
SEND

Browse by: All Products | China Suppliers Service is provided by Bossgoo.com

Copyright © 2008-2024 Bossgoo Co., Ltd. All rights reserved.

Your use of this website constitutes acknowledgement and acceptance of our Terms & Conditions